Yulia Shevtsova
Research Subjects
Yulia Shevtsova has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey S. Kononikhin
V.I. Kulakov National Medical Research Center for Obstetrics Gynecology and Perinatology, Ministry of Healthcare of Russian Federation, 117997 Moscow, Russia
1 shared publication - Alexander A. Yakovlev
Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia
1 shared publication - Alexey Yashchenok
Skolkovo Institute of Science and Technology, Skolkovo Innovation Center, 121205 Moscow, Russia
1 shared publication - Anna E. Bugrova
ФГБУН «Институт биохимической физики им. Н.М. Эмануэля» Российской академии наук, Москва, Российская Федерация
1 shared publication - Denis N. Silachev
A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia
1 shared publication - Dmitry Alexandrovich Gorin
Skolkovo Institute of Science and Technology
1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by Elsevier in SSRN Electronic Journal
Depth filtration coupled with proteomics identifies colorectalcancer-specific extracellular vesicle protein corona as potential biomarker
The clinical translation of extracellular vesicle (EV)-based diagnostics remains hindered by the lack of rapid, non-degradative, and scalable isolation methods compatible with robust biomarker discovery. In this study we use express asymmetric depth filtration method and compare it directly with ultrafiltration coupled with size-exclusion chromatography for EV isolation from two colorectal cancer cell lines, HCT116 and HT29. The two methods yield distinct EV subpopulations, with depth filtration providing faster processing and good purity suitable for proteomics. Using depth filtration, we performed comparative proteomic profiling of EVs from CRC, ovarian (SKOV3), and breast (SKBR3) cancer cell lines to identify candidate CRC-associated protein markers. To assess clinical relevance, we then isolated EVs from the blood plasma of healthy donors and stage III CRC patients using depth filtration and analyzed their proteomes. Six proteins were overexpressed in both CRC cell line EVs and plasma-derived CRC EVs relative to the other cancer types and healthy controls. Three of these six proteins – fibrinogen gamma, fibronectin, and vitronectin, each of which is a surface EVs protein – were validated by ELISA in an independent cohort (12 CRC patients, 8 healthy donors), confirming their elevated expression on CRC patient plasma EVs. Notably, EV-associated protein levels showed better stage discrimination (stage I–II vs. III–IV) than total plasma protein levels. These findings demonstrate that depth filtration enables rapid, clinically compatible EV isolation and that comparative proteomics of cell line and plasma EVs can identify robust, stage-sensitive CRC biomarkers for liquid biopsy development.
- 26 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDepth filtration coupled with proteomics identifies colorectalcancer-specific extracellular vesicle protein corona as potential biomarker
The clinical translation of extracellular vesicle (EV)-based diagnostics remains hindered by the lack of rapid, non-degradative, and scalable isolation methods compatible with robust biomarker discovery. In this study we use express asymmetric depth filtration method and compare it directly with ultrafiltration coupled with size-exclusion chromatography for EV isolation from two colorectal cancer cell lines, HCT116 and HT29. The two methods yield distinct EV subpopulations, with depth filtration providing faster processing and good purity suitable for proteomics. Using depth filtration, we performed comparative proteomic profiling of EVs from CRC, ovarian (SKOV3), and breast (SKBR3) cancer cell lines to identify candidate CRC-associated protein markers. To assess clinical relevance, we then isolated EVs from the blood plasma of healthy donors and stage III CRC patients using depth filtration and analyzed their proteomes. Six proteins were overexpressed in both CRC cell line EVs and plasma-derived CRC EVs relative to the other cancer types and healthy controls. Three of these six proteins – fibrinogen gamma, fibronectin, and vitronectin, each of which is a surface EVs protein – were validated by ELISA in an independent cohort (12 CRC patients, 8 healthy donors), confirming their elevated expression on CRC patient plasma EVs. Notably, EV-associated protein levels showed better stage discrimination (stage I–II vs. III–IV) than total plasma protein levels. These findings demonstrate that depth filtration enables rapid, clinically compatible EV isolation and that comparative proteomics of cell line and plasma EVs can identify robust, stage-sensitive CRC biomarkers for liquid biopsy development.